Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor
Jang, Seong, Strickland, Bill, Finis, Lynda, Kooijman, Jeffrey J., Melis, Janneke J. T. M., Zaman, Guido J. R., Van Tornout, Jan
Published in Cancer chemotherapy and pharmacology (01.06.2023)
Published in Cancer chemotherapy and pharmacology (01.06.2023)
Get full text
Journal Article
Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020
Kooijman, Jeffrey J, van Riel, Wilhelmina E, Dylus, Jelle, Prinsen, Martine B W, Grobben, Yvonne, de Bitter, Tessa J J, van Doornmalen, Antoon M, Melis, Janneke J T M, Uitdehaag, Joost C M, Narumi, Yugo, Kawase, Yusuke, de Roos, Jeroen A D M, Willemsen-Seegers, Nicole, Zaman, Guido J R
Published in Frontiers in oncology (14.09.2022)
Published in Frontiers in oncology (14.09.2022)
Get full text
Journal Article
Abstract 1080: Altered response to BET-bromodomain inhibitors JQ1 and I-BET-762 targeting c-Myc in erdafitinib-resistant endometrial carcinoma cell line AN3 CA
VAN RIEL, Wilhelmina E, Melis, Janneke J., Vogels, Demi H., Mulder, Winfried R., Kooijman, Jeffrey J., Buijsman, Rogier C., Zaman, Guido J.
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Get full text
Journal Article
Abstract 4014: Comparative biochemical kinase activity analysis identifies rivoceranib as the most selective VEGFR-2 inhibitor compared with other TKIs with known activity against VEGFR-2
Jang, Seong, Strickland, Bill, Finis, Lynda, Koojiman, Jeffrey J., Melis, Janneke J., Zaman, Guido J., Tornout, Jan V.
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article
Abstract 7126: Synergistic combinations and tissue type-specificity of compounds targeting components of the DNA damage response pathway in 2D culture and 3D spheroid cell viability assays
Melis, Janneke J., Kluitmans, Daphne J., Kooijman, Jeffrey J., Dylus, Jelle, Wetemans, Sabine, Geerdink-Datema, Suzan, de Roos, Jeroen A., Grobben, Yvonne, Zaman, Guido J.
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Get full text
Journal Article
Abstract 620: Screening of small-molecule MAPK pathway inhibitors on a panel of 130 human cancer cell lines identifies determinants of response in RAS -mutant subgroups
Kooijman, Jeffrey J., Al Koerdi, Awan, Kluitmans, Daphne J., van den Bossche, Esmee, Dylus, Jelle, de Roos, Jeroen A., Melis, Janneke J., Zaman, Guido J.
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Get full text
Journal Article
Abstract 4668: Characterization of fourth-generation EGFR inhibitors in binding experiments with C797S mutant EGFR and cell-based assays with osimertinib-resistant non-small cell lung cancer cell lines
Melis, Janneke J., Kevenaar, Kirsten, Kooijman, Jeffrey J., Grobben, Yvonne, Ytsma, Jacob, Bertran-Alamillo, Jordi, Molina-Vila, Miguel-Angel, Willemsen-Seegers, Nicole, Zaman, Guido J.
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Get full text
Journal Article
Abstract 619: Comprehensive cell line profiling of monomer- and dimer-selective small molecule RAF inhibitors uncovers determinants of cellular responses
Kooijman, Jeffrey J., Koerdi, Awan Al, van der Leeuw, Sjoerd B., Kluitmans, Daphne J., van den Bossche, Esmee, Dylus, Jelle, de Roos, Jeroen A., Melis, Janneke J., Willemsen-Seegers, Nicole, Zaman, Guido J.
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Get full text
Journal Article